Business Wire Feed

CEL-SCI Reports Fiscal Third Quarter 2026 Results

August 17th, 2026|

Peer-reviewed study in Oral Oncology identified prognostic biomarkers for selecting patients most likely to achieve substantial survival benefit from Multikine in upcoming Confirmatory Head & Neck Cancer Registration Study Dual track commercialization strategy includes the more...

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb’s First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

August 13th, 2026|

Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new more...

AIVITA Biomedical Nominated for 2026 Prix Galien USA Award

August 13th, 2026|

Nomination recognizes AIVITA’s personalized immunotherapy platform and its potential to advance cancer treatment and infectious-disease preparednessIRVINE, Calif.--(BUSINESS WIRE)--AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of more...

H.B. Fuller Announces AMS Shareholders Approve Proposed Acquisition

August 13th, 2026|

ST. PAUL, Minn.--(BUSINESS WIRE)--H.B. Fuller Company (“H.B. Fuller”) (NYSE: FUL), the world’s largest pureplay adhesives company, today announced that shareholders of Advanced Medical Solutions Group plc (“AMS”) (LSE:AMS) approved H.B. Fuller’s proposed acquisition of AMS more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.